TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05208996
Drug: siCoV/KK46
Approvals — FDA: no, EMA: no, PMDA: no
Description: The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg.
Study: NCT06717672
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline used is an iv fluid given for fluid replacement
Study: NCT04823897
Drug: CCI-001
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase.
Study: NCT04849728
Drug: IVA337
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
Study: NCT06331663
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: first start with remifentanil 5.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. Inadequate antinociception (Surgical Pleth Index(SPI) \> 80 and hyperdynamics (the increased heart rate (HR) and mean blood pressure (MBP) above 20% of baseline or HR\>100bpm and arterial blood pressure(ABP)\>180/100mmHg)) is defined as failure, therefore we increase remifentanil by 0.5 ng/ml; otherwise, the setting is considered successful without abovementioned situations.
Study: NCT04849728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
Study: NCT05798793
Drug: TP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
Study: NCT06729840
Drug: Injection
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D , botox , tramcinolone intralesionally injected in keloid
Study: NCT05470049
Drug: SHR8554 Injection and SHR0410 Injection
Normalized name: INFLAMMATION AND INFECTION DETECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group A: SHR8554 Injection and SHR0410 Injection; high dose
Study: NCT05470049
Drug: SHR8554 Injection and SHR0410 Injection
Normalized name: INFLAMMATION AND INFECTION DETECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group B: SHR8554 Injection and SHR0410 Injection; low dose
Study: NCT05470049
Drug: SHR8554 Injection and Placebo for SHR0410 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection
Study: NCT06310811
Drug: RD06-04 Cells injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be treated with RD06-04 cells when enrolled in the study
Study: NCT05807529
Drug: 2ccPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms.~Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29
Study: NCT05807529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29
Study: NCT00442273
Drug: Umbilical cord serum eyedrops
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06334549
Drug: Norepinephrine-P
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: after induction of anesthesia, use total intravenous anesthesia maintained with propofol
Study: NCT06334549
Drug: Norepinephrine-S
Approvals — FDA: no, EMA: no, PMDA: no
Description: after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
Study: NCT05042817
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9%
Study: NCT05042817
Drug: 50 mg prilocaine + 2.5 mcg sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg prilocaine + 2.5 mcg sufentanil
Study: NCT04846309
Drug: FMISO PET CT
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to the start of study therapy, eligible subjects will receive a FMISO-PET scan. If there is uptake visualized on the scan, the tumor will be considered as hypoxic. If there is no uptake seen on the FMISO-PET scan, tumors will be labeled not hypoxic.
Study: NCT03219450
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.
Study: NCT04535427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Study: NCT05323214
Drug: Control Analgesic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: testing the efficiency of bupivacaine without adjuvant drugs in epidural analgesia
Study: NCT05323214
Drug: Fentanyl Analgesic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: testing the efficiency of Fentanyl as an adjuvant drug to bupivacaine in epidural analgesia
Study: NCT05150431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.
Study: NCT04816916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered TID with food
Study: NCT05341401
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is a corticosteroid used as a standard therapy for management of ulcerative colitis
Study: NCT05923515
Drug: JMKX000197
Approvals — FDA: no, EMA: no, PMDA: no
Description: for injection
Study: NCT05922384
Drug: KL-7SHRNA injection solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients continue to receive HAART throughout treatment until meet the criteria of interruption of HAART.
Study: NCT04986839
Drug: Ibuprofen injection
Normalized name: ibuprofen Injection
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Ibuprofen
Study: NCT06213987
Drug: 0.025% Tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total duration of 8 weeks.
Study: NCT05292196
Drug: TQC3721 suspension for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
Study: NCT05292196
Drug: TQC3721 suspension placebo for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
Study: NCT00001989
Drug: Trichosanthin
Normalized name: Trichosanthes kirilowii fruit rind
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00240799
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05684744
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will receive methotrexate in a dose of 0.2- 0.4 mg/kg/week for 12 weeks
Study: NCT06204952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In patients with facet joint syndrome, placebo drug is administered at a dosage of 1 tablet three times a day for 12 weeks.
Study: NCT04927247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
Study: NCT06417697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule formulation
Study: NCT04732065
Drug: ONC206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally (PO)
Study: NCT06487845
Drug: BAY3283142
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR tablets, oral
Study: NCT06487845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to BAY3283142
Study: NCT03520751
Drug: scAAV1.tMCK.NTF3
Approvals — FDA: no, EMA: no, PMDA: no
Description: gene vector
Study: NCT05593445
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study: NCT04489134
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
Study: NCT04489134
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a 2 mg dose of LCP-tacro (Envarsus®)
Study: NCT04489134
Drug: Treament C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
Study: NCT06727890
Drug: Danshen Dripping Pill
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen Dripping Pill, 10 pills once, three times a day
Study: NCT06727890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 10 pills once, three times a day
Study: NCT06728644
Drug: L-arginine intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine intervention for 3 months, 3 g per day.
Study: NCT04805671
Drug: ADG20
Normalized name: Adintrevimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ADG20
Study: NCT04805671
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of normal saline
Study: NCT04652557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no active component
Study: NCT05555862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo intra-anal suppository
Study: NCT05345457
Drug: Azithromycin Pill
Normalized name: azithromycin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days).
Study: NCT05279859
Drug: ERAS-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05279859
Drug: ERAS-601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06358872
Drug: Azithromycin for Oral Suspension
Normalized name: Azithromycin for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.
Study: NCT05852093
Drug: Celecoxib+Buprenorphine Transdermal Patch
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NSAIDs+narcotic analgesics
Study: NCT05852093
Drug: Celecoxib+Buprenorphine Transdermal Patch+Tizanidine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NSAIDs+narcotic analgesics+Skeletal Muscle Relaxant
Study: NCT06306131
Drug: Meloxicam 15 milligram
Normalized name: meloxicam 15 MILLIGRAM In 1 TABLET ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
Study: NCT05507489
Drug: Jinzhen oral liquid or Jinhuaqinggan granules
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinzhen oral liquid, for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day.The dosage and usage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition. The drugs were medicated for 14 days.
Study: NCT00534898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05652647
Drug: Oral [14C]PF-07081532
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of \[14C\]PF-07081532, will be administered as a liquid formulation in study period 1.
Study: NCT05652647
Drug: Oral PF-07081532 and IV [14C]PF-07081532
Approvals — FDA: no, EMA: no, PMDA: no
Description: In study period 2: a single, oral, unlabeled dose of PF-07081532 will be administered as a liquid formulation. Approximately 1 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-07081532 will be administered via intravenous infusion.
Study: NCT06081153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description.
Study: NCT04914429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as a SC injection.
Study: NCT06610266
Drug: Weifuchun
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be instructed to take four tablets (1400mg) of Weifuchun three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
Study: NCT06610266
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be instructed to take one tablet (5mg) of folic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
Study: NCT06609525
Drug: CTO0303-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: eye drop, 1 drop 3 times (every 5 minutes) a day
Study: NCT06609525
Drug: CTO0303-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: eye drop, 1 drop 3 times (every 5 minutes) a day
Study: NCT05157269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two matching placebo tablets administered orally twice daily for 5 days
Study: NCT06610487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06609980
Drug: autologous fecal matter transplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous fecal matter transplant will be used to re-seed the child's gut with his or her own personalized microbiome composition which was preserved prior to antibiotics use.
Study: NCT05117060
Drug: LEO 152020 tablet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R) and prevent histamine from binding to the receptor. LEO 152020 is a tablet for oral administration.
Study: NCT05117060
Drug: LEO 152020 placebo tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEO 152020 placebo tablet contains the same excipients in the same concentration as LEO 152020 tablet, except that it does not contain the medical ingredient LEO 152020. LEO 152020 placebo is a tablet for oral administration.
Study: NCT05241938
Drug: Prostaglandin analogue eye drops
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
Study: NCT05630820
Drug: Bepirovirsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen will be administered.
Study: NCT04357951
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
Study: NCT00301587
Drug: Norgestimate-ethinyl estradiol, with or without folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02355054
Drug: C-11 Choline PET Imaging
Normalized name: choline C-11
DrugBank: Choline C-11 (DB09563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive IV injection of C-11 Choline followed by imaging from the base of the brain to the upper thigh on a PET/CT or a PET/MRI scanner
Study: NCT05379036
Drug: prescribing anapproved drug, examination
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Blood test to assess serum zonulin levels;~* Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~* Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months.
Study: NCT05152420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMX-C001 matched placebo
Study: NCT06172387
Drug: intra-arterial infusion albumin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The experimental group would inject 20% human blood albumin solution into the responsible blood vessel supply area by catheter artery at a dose of 0.6g/kg. The infusion time is 20-30 minutes. All participant will receive mechanical thrombectomy and a standard clinical therapy.
Study: NCT06153069
Drug: Short-course regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally.
Study: NCT00000689
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000689
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000689
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000689
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05652855
Drug: MHB088C for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHB088C for Injection, an antibody drug-conjugated molecule (ADC)
Study: NCT06153069
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally.
Study: NCT04640480
Drug: SNB-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting
Study: NCT06307106
Drug: ketorolac and light marcaine
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: local injection at surgical site of 30 mg ketorolac and 7-1.5 mg\\kg\\dose light marcaine
Study: NCT06307106
Drug: Corticosteroids injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: local injection at surgical site of 40 mg\\ dose of dexamethasone
Study: NCT06307106
Drug: Diclofenac Sodium Gel
Normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical application of Diclofenac Sodium Gel
Study: NCT06449235
Drug: Sulphonylureas
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical Name: Sulphonylureas Class: Sulphonylureas~Mechanism of Action:~Stimulates insulin release from pancreatic beta cells. Enhances the sensitivity of beta cells to glucose. Reduces hepatic glucose production. Increases peripheral glucose uptake and utilization. Administration: Typically administered once or twice daily, depending on the specific medication and patient needs.
Study: NCT06449235
Drug: Other DPP4-i
Normalized name: Other i.v. solution additives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical Names: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Alogliptin Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Typically administered orally once daily. Dosage may vary depending on the specific medication and patient needs.